The antibody trastuzumab, targeted to inhibit the signalling of ErbB2, a tyrosine kinase receptor overexpressed in 20-30% of breast cancers, improves the prognosis in women affected by this tumour, but produces cardiotoxicity, since ErbB2 is also involved in myocardial homeostasis. In this review, we discuss the pathophysiology of trastuzumab cardiomyopathy and the complex interplay between ErbB2 inhibition and anthracyclines, and we focus on the actual challenges of detecting, monitoring, and managing trastuzumab cardiotoxicity: the research of new, sensitive markers of early trastuzumab toxicity, before the ejection fraction is reduced, is an active field of research.
Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge / Tocchetti, CARLO GABRIELE; G., Ragone; C., Coppola; D., Rea; G., Piscopo; Scala, Stefania; DE LORENZO, Claudia; R. V., Iaffaioli; C., Arra; N., Maurea. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1388-9842. - 14:(2012), pp. 130-137. [10.1093/eurjhf/hfr165]
Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge
TOCCHETTI, CARLO GABRIELE;SCALA, STEFANIA;DE LORENZO, CLAUDIA;
2012
Abstract
The antibody trastuzumab, targeted to inhibit the signalling of ErbB2, a tyrosine kinase receptor overexpressed in 20-30% of breast cancers, improves the prognosis in women affected by this tumour, but produces cardiotoxicity, since ErbB2 is also involved in myocardial homeostasis. In this review, we discuss the pathophysiology of trastuzumab cardiomyopathy and the complex interplay between ErbB2 inhibition and anthracyclines, and we focus on the actual challenges of detecting, monitoring, and managing trastuzumab cardiotoxicity: the research of new, sensitive markers of early trastuzumab toxicity, before the ejection fraction is reduced, is an active field of research.File | Dimensione | Formato | |
---|---|---|---|
Eur J Heart Fail-2012-Tocchetti-130-7.pdf
solo utenti autorizzati
Tipologia:
Documento in Post-print
Licenza:
Accesso privato/ristretto
Dimensione
246.14 kB
Formato
Adobe PDF
|
246.14 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.